immatics is a biopharmaceutical company dedicated to the development of innovative cancer immunotherapeutics.

immatics' proprietary technology for the identification of tumor-associated peptides (TUMAPs) enables the development of novel anti-cancer vaccines for multiple cancer indications. immatics is currently developing two multi-TUMAP products in clinical phase II studies – IMA901 for the treatment of renal cell carcinoma (RCC) and IMA910 for the treatment of colorectal carcinoma (CRC). Further product candidates are currently in pre-clinical development.
immatics was founded in 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen (Prof. Hans-Georg Rammensee) and was able to raise more than 54 mill. Euros in two financing rounds (2004 and 2007) as yet. The company is based in Tuebingen and in Munich, both in Germany.
www.immatics.com